Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics.
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program.
According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.
Positive
- Japan and Mexico grant new patents for DNA Polymerase IIIC inhibitors
- Portfolio expanded to six U.S. and ten international patents
- Patents cover compositions of matter, methods of use, and pharmaceutical compositions
- IP protection explicitly covers ibezapolstat and the ACX‑375C program
- Additional country-level patent applications are still under review, indicating possible further IP growth
Details
Market move: ACXP +4.76% in the Aug 12 session. international patent grants
On Aug 12, the day this news came out, ACXP closed 4.76% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day. Relative volume reached 11.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 12 session.
Key Figures
- New patents granted
- 2 patents
- Japan and Mexico patent offices
- U.S. patents
- 6 patents
- Acurx patent portfolio
- International patents
- 10 patents
- Acurx patent portfolio
Historical Context
-
Leiden partnership advanced structural studies of DNA Polymerase IIIC inhibitor antibiotics.
-
FDA discussed a potential single-Phase 3 registration path for ibezapolstat.
-
Microbiome and in vitro data supported ibezapolstat’s activity in recurrent CDI.
-
Acurx scheduled its second-quarter 2026 financial-results conference call.
-
Cryo-EM results mapped ibezapolstat bound to Gram-positive DNA Polymerase IIIC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dna polymerase iiic technical
compositions-of-matter regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
David P. Luci, President and Chief Executive Officer of Acurx, stated: "Achieving these additional new patents extend our patent estate protection as we further develop ibezapolstat and our innovative, AI-supported drug discovery platform."
Robert J. DeLuccia, Executive Chairman of Acurx, stated, "We believe Acurx's ibezapolstat and preclinical pipeline of systemically absorbed antibiotics has the potential to create a transformational shift in the treatment paradigm of certain serious and potentially life-threatening infections without promoting antibiotic-induced gut dysbiosis. These infections include C. difficile, acute bacterial skin and skin-structure infections (ABSSSI, including MRSA), Community-acquired bacterial pneumonia (CABP), hospital and/or ventilator-associated bacterial pneumonia (HABP/VABP), bacteremia with or without sepsis and/or infectious endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax, caused by B. anthracis, a Bioterrorism Category A Threat-Level pathogen."
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).
Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection (CDI) is Phase 3 ready to advance to international clinical trials subject to obtaining appropriate financing. Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support indications for both treatment and reduction of recurrence of Clostridioides difficile Infection (CDI). FDA stated that it is open to further discussion on the totality of evidence from the clinical development program at a pre-NDA meeting after completion of a single Phase 3 trial and any other clinical trials conducted prior to the pre-NDA meeting, particularly if the clinical efficacy results are robust. Additionally, the Agency agreed that a successful clinical outcome from a single IBZ-ASPIRE Phase 3 trial, supported by the open-label IBZ-PATHFINDER Phase 2 trial in multiply-recurrent CDI (rCDI) may allow NDA filing for both the treatment of acute CDI and the reduction of recurrence of rCDI. Trial start-up activities for the IBZ-PATHFINDER ground-breaking clinical trial in patients with rCDI have been initiated with patient enrollment to begin in the next few months.
The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on March 12 2026, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/japan-and-mexico-patent-offices-both-grant-acurx-pharmaceuticals-new-patents-for-dna-polymerase-iiic-inhibitor-antibiotics-302849336.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.